A Phase II Study of Lenalidomide (Revlimid) in Combination with Rituximab as Initial Treatment for Patients with Indolent Non-Hodgkin's Lymphoma (NHL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 13 Feb 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 13 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 13 Jul 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.